Filter Results
:
(173)
Show Results For
-
All HBS Web
(632)
- Faculty Publications (173)
Show Results For
-
All HBS Web
(632)
- Faculty Publications (173)
- June 2004 (Revised June 2006)
- Supplement
Vertex Pharmaceuticals: R&D Portfolio Management (A)
By: Gary P. Pisano, Lee Fleming and Eli Strick
Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will...
View Details
Pisano, Gary P., Lee Fleming, and Eli Strick. "Vertex Pharmaceuticals: R&D Portfolio Management (A)." Harvard Business School Supplement 604-101, June 2004. (Revised June 2006.)
- June 2003 (Revised May 2006)
- Case
Cipla
By: Rohit Deshpande and Laura Winig
The head of Cipla, a $325-million-dollar Indian pharmaceutical company and seller of low-cost AIDS drugs to South Africa, must decide what to do about Cipla's future. With India poised to enforce international patents in only two years, much of Cipla's product line...
View Details
- February 2003 (Revised August 2005)
- Case
UCB (A): Managing Information for Globalization and Innovation
By: F. Warren McFarlan and Brian DeLacey
This case presents a complex total MIS strategy case for a $3 billion European pharmaceutical/chemicals company based in Brussels. It covers corporate strategy alignment of IT portfolio, IT operations issues, and global coordination of IT.
View Details
Keywords:
Information Technology;
Operations;
System;
Corporate Strategy;
Investment Portfolio;
Globalization;
Pharmaceutical Industry;
Pharmaceutical Industry;
Brussels
McFarlan, F. Warren, and Brian DeLacey. "UCB (A): Managing Information for Globalization and Innovation." Harvard Business School Case 303-091, February 2003. (Revised August 2005.)
- June 2002 (Revised November 2005)
- Case
Life, Death, and Property Rights: The Pharmaceutical Industry Faces AIDS in Africa
By: Debora L. Spar
In the final years of the 20th century, the world was hit by a plague of epidemic proportions--AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought under control through a...
View Details
Keywords:
Patents;
Health Pandemics;
Corporate Social Responsibility and Impact;
Pharmaceutical Industry;
Africa
Spar, Debora L., and Nick Bartlett. "Life, Death, and Property Rights: The Pharmaceutical Industry Faces AIDS in Africa." Harvard Business School Case 702-049, June 2002. (Revised November 2005.)
- February 2002
- Case
Fighting AIDS and Pricing Drugs
In early 2001, makers of AIDS drugs were suing to prevent developing countries from violating their patents. The issue was driven by price. The developing countries could not afford the market price for these drugs. At the same time, the drug companies were reluctant...
View Details
Keywords:
Developing Countries and Economies;
Patents;
Price;
Strategy;
Globalized Markets and Industries;
Pharmaceutical Industry
Gourville, John T. "Fighting AIDS and Pricing Drugs." Harvard Business School Case 502-061, February 2002.
- August 2001 (Revised March 2008)
- Case
Helios Health (A)
By: Regina E. Herzlinger and Alfred Martin
Helios PC system provides personalized drug information to the patients in the doctor's waiting room. It has met with considerable consumer acceptance and a very high return for the drug companies that sponsor it. What price should it charge them for the service?
View Details
Keywords:
Entrepreneurship;
Price;
Health Care and Treatment;
Information Publishing;
Innovation and Invention;
Product Marketing;
Demand and Consumers;
Pharmaceutical Industry;
Pharmaceutical Industry
Herzlinger, Regina E., and Alfred Martin. "Helios Health (A)." Harvard Business School Case 302-022, August 2001. (Revised March 2008.)
- July 2001 (Revised August 2005)
- Case
Medicines Company, The
It is early 2001 and the Medicines Co. just received FDA approval to market Angiomax, a blood thinner to be used during angioplasties and heart procedures. It is intended to be a better alternative to Heparin, an 80-year-old drug that costs less then $10 per dose. The...
View Details
Keywords:
Business Model;
Change Management;
Decision Choices and Conditions;
Cost Management;
Price;
Product Marketing;
Product Launch;
Product Development;
Risk and Uncertainty;
Pharmaceutical Industry;
Pharmaceutical Industry
Gourville, John T. "Medicines Company, The." Harvard Business School Case 502-006, July 2001. (Revised August 2005.)
- January 2001
- Case
Abgenix and the XenoMouse
By: Robert J. Dolan
Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to...
View Details
Keywords:
Product Development;
Marketing Strategy;
Health Testing and Trials;
Risk and Uncertainty;
Technological Innovation;
Innovation Strategy;
Science-Based Business;
Biotechnology Industry
Dolan, Robert J. "Abgenix and the XenoMouse." Harvard Business School Case 501-061, January 2001.
- January 2001 (Revised July 2003)
- Case
Pharmacyclics: Financing Research & Development
By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more...
View Details
Keywords:
Valuation;
Cash Flow;
Financing and Loans;
Business Startups;
Financial Strategy;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry
Baker, Malcolm P., Richard S. Ruback, and Aldo Sesia. "Pharmacyclics: Financing Research & Development." Harvard Business School Case 201-056, January 2001. (Revised July 2003.)
- December 2000 (Revised January 2001)
- Background Note
Promise of Functional Foods, The
By: Ray A. Goldberg, Carin-Isabel Knoop and Laure Mougeot Stroock
This case presents a definition of functional foods or nutraceuticals (food or food ingredients that could provide a health benefit beyond the traditional nutrients they contain), a description of some of the major obstacles to their commercialization and...
View Details
Keywords:
Food;
Private Sector;
Public Sector;
Health;
Product Development;
Production;
Commercialization;
Pharmaceutical Industry;
Pharmaceutical Industry
Goldberg, Ray A., Carin-Isabel Knoop, and Laure Mougeot Stroock. "Promise of Functional Foods, The." Harvard Business School Background Note 901-013, December 2000. (Revised January 2001.)
- October 2000 (Revised June 2017)
- Case
Vyaderm Pharmaceuticals: The EVA Decision
By: Robert Simons and Indra A. Reinbergs
In 2016, the new CEO of Vyaderm Pharmaceuticals introduces an Economic Value Added (EVA) program to focus the company on long-term shareholder value. The EVA program consists of three elements: EVA centers (business units), EVA drivers (operational practices that...
View Details
Keywords:
Compensation and Benefits;
Employee Relationship Management;
Economic Growth;
Economic Systems;
Management;
Motivation and Incentives;
Organizational Design;
Organizational Structure;
Performance Evaluation;
Decision Choices and Conditions;
Pharmaceutical Industry;
Washington (state, US)
Simons, Robert, and Indra A. Reinbergs. "Vyaderm Pharmaceuticals: The EVA Decision." Harvard Business School Case 101-019, October 2000. (Revised June 2017.)
- December 1999
- Case
Agrochemicals at Ciba-Geigy AG (A)
By: Michael L. Tushman, Wendy Smith and Daniel Radov
After spending five years to develop a revolutionary product, the director of Ciba-Geigy's fungicide research department is handed an unfavorable market study. The case details the R&D process for the new product, including information on corporate partnerships,...
View Details
Keywords:
Agribusiness;
Plant-Based Agribusiness;
Research and Development;
Innovation and Invention;
Innovation Strategy;
Product Launch;
Marketing Channels;
Change Management;
Product Development;
Business Processes;
Organizational Structure;
Corporate Accountability;
Pharmaceutical Industry;
Pharmaceutical Industry
Tushman, Michael L., Wendy Smith, and Daniel Radov. "Agrochemicals at Ciba-Geigy AG (A)." Harvard Business School Case 400-022, December 1999.
- March 1999
- Case
Merck & Co., Inc.: Corporate Strategy, Organization and Culture (A)
By: Michael Beer and Perry Fagan
In the early 1990s, Merck faced a series of challenges because of significant changes in its competitive and regulatory environment (e.g., growth in power of pharmaceutical buyers like managed care organizations led to price pressures and President Clinton's review of...
View Details
Keywords:
Organizational Change and Adaptation;
Business or Company Management;
Organizational Culture;
Problems and Challenges;
Management Practices and Processes;
Competitive Strategy;
Management Teams;
Health Care and Treatment;
Governing Rules, Regulations, and Reforms;
Situation or Environment;
Alignment;
Pharmaceutical Industry;
United States
Beer, Michael, and Perry Fagan. "Merck & Co., Inc.: Corporate Strategy, Organization and Culture (A)." Harvard Business School Case 499-054, March 1999.
- November 1997 (Revised November 2010)
- Case
Hikma Pharmaceuticals (A)
By: John A. Quelch
The president of a Jordanian pharmaceutical company is contemplating how to further penetrate the U.S. market, either through its own manufacturing and sales efforts, or as a supplier to a third party.
View Details
Keywords:
Entrepreneurship;
Globalized Markets and Industries;
Emerging Markets;
Expansion;
Pharmaceutical Industry;
Jordan;
United States
Quelch, John A., and Robin Root. "Hikma Pharmaceuticals (A)." Harvard Business School Case 598-019, November 1997. (Revised November 2010.)
- September 1997 (Revised October 1997)
- Case
Bayer AG (A)
By: John A. Quelch
Bayer's senior executives convene in Germany to consider submitting a $1 billion bid that would recover the Bayer brand name and trademark cross in North America, both of which were confiscated by the U.S. government after World War I. The group also sets out to assess...
View Details
Keywords:
Management Teams;
Brands and Branding;
War;
Communication;
Trademarks;
Acquisition;
Government and Politics;
Pharmaceutical Industry;
Pharmaceutical Industry;
Germany;
North America;
United States
Quelch, John A., and Robin Root. "Bayer AG (A)." Harvard Business School Case 598-031, September 1997. (Revised October 1997.)
- February 1997
- Case
Archer Daniels Midland: Direction and Strategy
By: Ray A. Goldberg and Thomas N. Urban Jr
Sets out the strategy and competitive competencies of one of the leading grain trade and processing companies in the world. An overview of the company's innovations in corn and oilseed by-products is provided. The strategy of the firm is to add by-products to corn,...
View Details
Keywords:
Innovation and Invention;
Strategic Planning;
Business Strategy;
Value Creation;
Pharmaceutical Industry;
Pharmaceutical Industry
Goldberg, Ray A., and Thomas N. Urban Jr. "Archer Daniels Midland: Direction and Strategy." Harvard Business School Case 597-039, February 1997.
- February 1996
- Case
Chadwick, Inc.: The Balanced Scorecard (Abridged)
By: Robert S. Kaplan
The pharmaceutical division of a diversified company has been asked to develop a Balanced Scorecard. Research and development projects take about ten years to bring a new product to the marketplace and the division depends on good relations and active feedback from its...
View Details
Keywords:
Balanced Scorecard;
Research and Development;
Product Launch;
Commercialization;
Consumer Behavior;
Customer Focus and Relationships;
Performance Evaluation;
Pharmaceutical Industry
Kaplan, Robert S. "Chadwick, Inc.: The Balanced Scorecard (Abridged)." Harvard Business School Case 196-124, February 1996.
- January 1996
- Case
Biogen, Inc.: rBeta Interferon Manufacturing Process Development
Biogen, Inc., a Cambridge, MA-based biotechnology company, is wrapping up a project to develop a new manufacturing process for a new drug product that will reposition the company from a purely research-oriented company to a fully integrated pharmaceutical manufacturing...
View Details
Keywords:
Learning;
Technological Innovation;
Management Analysis, Tools, and Techniques;
Product Development;
Organizational Change and Adaptation;
Projects;
Research and Development;
Corporate Strategy;
Biotechnology Industry
Wheelwright, Steven C. "Biogen, Inc.: rBeta Interferon Manufacturing Process Development." Harvard Business School Case 696-083, January 1996.
- September 1995
- Case
Ares-Serono
By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop
Ares Serono, a medium-size Swiss pharmaceutical company, is the global leader in the field of fertility drugs. The company has successfully transformed into one of the very few biotech firms in Europe. The case treats a set of major strategic and organizational...
View Details
Keywords:
Geographic Location;
Globalized Firms and Management;
Asset Management;
Balance and Stability;
Expansion;
Digital Platforms;
Leadership Development;
Health Care and Treatment;
Transformation;
Family Business;
Problems and Challenges;
Pharmaceutical Industry;
Pharmaceutical Industry;
Switzerland;
Europe
Yoshino, Michael Y., Jean-Pierre Jeannet, and Carin-Isabel Knoop. "Ares-Serono." Harvard Business School Case 396-035, September 1995.
- March 1994 (Revised March 1995)
- Case
Astra/Merck Group
By: Frank V. Cespedes and Marie Bell
Astra/Merck (A/M), originally a joint venture of AB Astra and Merck & Co., is preparing to be an independent company in 1993. Since the company does not engage in basic research and development of drugs, it is essentially a distribution organization. Fundamental to...
View Details
Keywords:
Cost vs Benefits;
Marketing Strategy;
Distribution;
Performance Evaluation;
Research and Development;
Risk and Uncertainty;
Sales;
Competitive Strategy;
Pharmaceutical Industry
Cespedes, Frank V., and Marie Bell. "Astra/Merck Group." Harvard Business School Case 594-045, March 1994. (Revised March 1995.)